Skip Navigation LinksHome > December 1, 2013 - Volume 64 - Issue 4 > Cost-Effectiveness of Newer Antiretroviral Drugs in Treatmen...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000002
Clinical Science

Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease

Bayoumi, Ahmed M. MD, MSc*,†,‡,§; Barnett, Paul G. PhD; Joyce, Vilija R. MS; Griffin, Susan C. MSc, BSc; Sun, Huiying PhD#,**; Bansback, Nick J. PhD††; Holodniy, Mark MD‡‡,§§; Sanders, Gillian PhD‖‖; Brown, Sheldon T. MD¶¶,##; Kyriakides, Tassos C. PhD***; Angus, Brian MD, PhD†††,‡‡‡; Cameron, D. William MD§§§; Anis, Aslam H. PhD**,††; Sculpher, Mark PhD; Owens, Douglas K. MD, MS‡‡,§§,‖‖‖

Supplemental Author Material
Collapse Box


Objective: Newer antiretroviral drugs provide substantial benefits but are expensive. The cost-effectiveness of using antiretroviral drugs in combination for patients with multidrug-resistant HIV disease was determined.

Design: A cohort state-transition model was built representing treatment-experienced patients with low CD4 counts, high viral load levels, and multidrug-resistant virus. The effectiveness of newer drugs (those approved in 2005 or later) was estimated from published randomized trials. Other parameters were estimated from a randomized trial and from the literature. The model had a lifetime time horizon and used the perspective of an ideal insurer in the United States. The interventions were combination antiretroviral therapy, consisting of 2 newer drugs and 1 conventional drug, compared with 3 conventional drugs. Outcome measures were life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness.

Results: Substituting newer antiretroviral drugs increased expected survival by 3.9 years in advanced HIV disease. The incremental cost-effectiveness ratio of newer, compared with conventional, antiretroviral drugs was $75,556/QALY gained. Sensitivity analyses showed that substituting only one newer antiretroviral drug cost $54,559 to $68,732/QALY, depending on assumptions about efficacy. Substituting 3 newer drugs cost $105,956 to $117,477/QALY. Cost-effectiveness ratios were higher if conventional drugs were not discontinued.

Conclusions: In treatment-experienced patients with advanced HIV disease, use of newer antiretroviral agents can be cost-effective, given a cost-effectiveness threshold in the range of $50,000 to $75,000 per QALY gained. Newer antiretroviral agents should be used in carefully selected patients for whom less expensive options are clearly inferior.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.